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Abstract
Background: Proteinuria is a manifestation of renal dysfunction and it has been demonstrated to be a significant
prognostic factor in various clinical situations. The study was designed to analyze prognosis of patients receiving
liver transplantation as well as to determine predictive performance of perioperative proteinuria.
Methods: We retrospectively reviewed data of patients who had received a liver transplant in a medical center between
2002 and 2010. Demographic information and clinical characteristic parameters were recorded on the day of intensive
care unit admission before operation and on postoperative days 1, 7, and 14.
Results: Among a total of 323 patients, in-hospital mortality and 90-day mortality rates were 13.0 % (42/323) and
14.2 % (46/323), respectively. Patients with proteinuria on admission had higher rates of acute kidney injury (26.8 %
vs. 8.8 %, p < 0.001), severe infection episodes (48.8 % vs. 30.7 %, p = 0.023), hospital death (31.1 % vs. 10.1 %,
p < 0.001), and 90-day mortality (37.7 % vs. 10.9 %, p < 0.001). Multivariate analysis showed that proteinuria on
admission and Sequential Organ Failure Assessment (SOFA) score were independent predictors of in-hospital mortality.
The discriminatory ability of proteinuria plus SOFA was even better than that of SOFA alone, especially on
postoperative day 1.
Conclusions: The presence of proteinuria before liver transplantation is supposed to be recognized as a negative
predictor for in-hospital survival. Moreover, the presence of proteinuria after liver transplantation can assist in the early
prediction of poor short-term prognosis for patients receiving liver transplantation.
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Background
Proteinuria has been suggested to be a predictive factor
and an important tool for differentiating the etiology of
renal dysfunction in various clinical scenarios [1, 2].
The good predictive performance of preoperative pro-
teinuria utilized for the development of renal failure
after operation has been reported [3]. Lin et al. also
demonstrated that the presence of proteinuria in patients
with end-stage liver disease is associated with increased
risk of intensive care unit (ICU) mortality and poor short-
term outcome [4].
In the literature, prognostic significance of several
scoring systems for end-stage liver disease has been
validated [5–7]. Wong and colleagues further compared
the predictive accuracy of the commonly used scores in
149 end-stage liver disease patients undergone liver
transplantation. The Sequential Organ Failure Assessment
(SOFA) system was found to be superior to Child-
Pugh points (CP points) and Model for End-Stage
Liver Disease (MELD) score, and postoperative day 7
SOFA had the best discriminative power for predict-
ing 3-month and 1-year mortality after liver trans-
plantation [8].
Renal dysfunction is one of the most significant
adverse events in patients awaiting or undergoing a liver
transplant, and its occurrence generally indicates a high
rate of poor prognosis [9, 10]. Prediction of acute kidney
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injury (AKI) is important for clinical decision making.
Numerous researches have demonstrated that the
presence of proteinuria provides a clue to the struc-
tural impairment of the kidney and reflects increased
risk of developing AKI in general population [11, 12].
In spite of the fact that proteinuria has been increas-
ingly considered as a significant manifestation of acute
or chronic renal disease [13], no study clarify the asso-
ciation between presence of proteinuria and prognosis
of patients undergoing liver transplant. This study
aims to assess proteinuria as an early marker of renal
dysfunction for liver transplant as well as to compare
the outcome prediction efficacy of proteinuria with
that of the main scores in the setting of liver
transplant.
Methods
Patient information and data collection
This research was performed from October 2002 to
December 2010 in a 2000-bed medical center in
Taiwan. A total of 323 patients with end-stage liver
disease and acute liver failure received liver trans-
plant were included. Patients less than 18 years of
age, patients who had previously received liver trans-
plant, and patients with end-stage renal disease were
excluded.
We retrospectively reviewed following data: demo-
graphic information, aetiologies of primary liver disease,
clinical parameters, donor type, anesthesia time, oper-
ation time, duration of hospitalization and ICU stay, and
outcome. Illness severity was evaluated on the day of
ICU admission before operation and on postoperative
day 1, 7, and 14. The primary outcome of this research
was in-hospital mortality rate. Follow-up at 90-day after
transplantation was performed by chart records review
or telephone interview [8].
Definitions
Urine dipstick analysis was used to detect proteinuria. The
results were graded as negative (less than 15 mg/dL), trace
(15 to 30 mg/dL), 1+ (30 to 100 mg/dL), 2+ (100 to
300 mg/dL), 3+ (300 to 1000 mg/dL) or 4+ (more than
1000 mg/dL). In this study, proteinuria was defined as
presence (urine dipstick reading trace, or ≥ 1+) or absence
(negative urine dipstick reading). The urinary analysis was
performed on ICU admission and postoperative days 1, 7,
and 14 [4].
Severity of liver disease was assessed by CP points
and MELD score [14, 15]. Severity of illness was also
graded by SOFA score according to the six organ sys-
tems. AKI was diagnosed according to definition of
the RIFLE criteria (Table 1). The RIFLE classification
was also used to classify patients into risk (RIFLE-R),
injury (RIFLE-I), and failure (RIFLE-F) groups [16].
No patient met the criteria for classification of loss of
kidney function (RIFLE-L) or end-stage renal disease
(RIFLE-E). The following simple model for mortality
was constructed: non–acute kidney injury (0 points),
RIFLE-R (1 point), RIFLE-I (2 points), and RIFLE-F
(3 points) [15]. The worst values measured on the
day of ICU admission and postoperative days 1, 7,
and 14 were recorded.
Statistical analysis
Data analyses were performed using the statistical pack-
age SPSS 19.0 (SPSS, Inc., Chicago, IL, USA). All statis-
tical tests are 2-tailed. A p- value of <0.05 is considered
to represent statistical significance. Continuous vari-
ables were presented as means and standard derivations,
and categorical data were summarized as frequency and
percentage unless otherwise stated. Hospital survivors
were compared with nonsurvivors in the primary
analysis. Kolmogorov–Smirnov test was employed
for testing normal distribution. Normally distributed
continuous variables were compared by Student’s t-test
and non-normally distributed ones were compared by
Mann–Whitney U test. Categorical data were tested by
the chi-square test. The risk factors for in-hospital
mortality were assessed by univariate analysis, and
statistically significant variables were included in
the multivariate analysis. For analyzing these variables,
backward multiple logistic regression model was
employed.
Hosmer–Lemeshow goodness-of-fit test was used to ex-
amined calibration and compare the number of predicted
and observed mortality. Discrimination in predicting
90-day mortality was assessed by area under the receiver
operating characteristic (AUROC) curve. Nonparametric
approach was used to compare the AUROC values. Ana-
lyses of the ROC curves were applied for calculating sensi-
tivity, specificity, and overall correctness. The cutoff value
was decided according to the ability to offer the highest
Youden index [17]. Cumulative survival curves were plot-
ted using the Kaplan-Meier method and compared by the
log rank test. Correlation of proteinuria and serum cre-
atinine (SCr) measured on ICU admission was measured
by Pearson analysis and linear regression. The prevalence
of proteinuria before operation, and on postoperative day
1, 7, and 14 were compared between 90-day survivors and
nonsurvivors by repeated-measures analysis of variance
using the general linear model procedure.
Results
Patient characteristics
Three hundred and twenty-three patients who received
liver transplant from October 2002 to December
2010 were enrolled. Overall in-hospital mortality rate
was 13.0 % (42/323). Table 2 listed patient data and
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Table 1 The criteria of SOFA score and RIFLE classification
SOFA Score 0 1 2 3 4
Respiration
PaO2/FiO2 >400 >300–≤ 400 >200–≤ 300 >100–≤ 200 with ventilator ≤100 with ventilator
Coagulation
Platelets, ×103/mm3 >150 >100–≤ 150 >50–≤ 100 >20–≤ 50 ≤20
Liver
Bilirubin, mg/dL (μmol/L) <1.2 (<20) ≥1.2–< 2.0 (20–32) ≥2.0–< 6.0 (33–101) ≥6.0–< 12.0 (102–204) ≥12.0 (>204)
Cardiovascular
Hypotension MAP ≥ 70 mm Hg MAP <70 mm Hg Dopamine ≤5 or
dobutamine (any dose)a
Dopamine >5 or epi ≤0.1
or norepi ≤0.1a
Dopamine >15 or epi >0.1
or norepi >0.1a
CNS




<1.2 (<110) ≥1.2–< 2.0 (110–170) ≥2.0–< 3.5 (171–299) ≥3.5–< 5.0 (300–440)
or <500 mL/day
≥5.0 (>440) or <200 mL/day
RIFLE Classification SCr criteria UO Criteria
Definition SCr changes over 1–7 days, sustained for more than 24 h UO < 0.5 ml/kg/h × 6 h
Risk Increase in SCr ≥ 1.5 × baseline or decrease in GFR≥ 25 % UO < 0.5 ml/kg/h × 6 h
Injury Increase in SCr ≥ 2.0 × baseline or decrease in GFR≥ 50 % UO < 0.5 ml/kg/h × 12 h
Failure Increase in SCr≥ 3.0 × baseline or an absolute serum creatinine≥ 4.0 mg/dl
with an acute rise of at least 0.5 mg/dl or decrease in GFR≥ 75 %
UO < 0.5 ml/kg/h × 24 h
or anuria × 12 h
Loss Complete loss of kidney function > 4 weeks
ESRD End-stage renal disease (>3 months)
aAbbreviations: SOFA the sequential organ failure assessment, RIFLE risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure, SCr serum creatinine, UO urine











clinical characteristics of both survivors and non-
survivors. Mean patient age was 51 years; 231 were male
(71 %) and 92 were female (29 %). Ninety-one patients
(28.2 %) received deceased-donor grafts. Mean length of
ICU stay was 21 days. There was no significant
difference in age or gender between survivors and non-
survivors. Table 3 listed primary liver diseases and pre-
sumptive causes of AKI on the first day after transplant-
ation. In this research, hepatitis B virus infection (34 %)
was the leading cause of liver diseases, followed by hepa-
titis B virus infection with hepatoma (15 %). Patient who
developed AKI tended to attribute to multiple reasons
(23 %), followed by infection (13 %).
Risk factors for adverse outcomes
Table 4 listed the correlation of operation time
and newly onset proteinuria after transplantation.
Among patients who received deceased-donor grafts,
Table 2 Patient demographic data and clinical characteristics according to in-hospital mortality
All patients (n = 323) Survivors (n = 281) Non-survivors (n = 42) P-value
Age (years) 50.8 ± 10.4 50.9 ± 9.8 50.3 ± 13.8 NS (0.753)
Gender (M/F) 231/92 199/82 32/10 NS (0.583)
BMI on admission (kg/m2) 24.3 ± 4.0 24.7 ± 4.0 21.1 ± 2.4 <0.001
History of diabetes mellitus (yes/no) 55/268 46/235 9/33 NS (0.387)
History of chronic kidney disease (yes/no) 31/292 22/259 9/33 0.005
Proteinuria on admission (yes/no) 45/278 31/250 14/28 <0.001
Hemoglobin on admission (g/dL) 10.6 ± 2.2 10.7 ± 2.2 9.8 ± 2.1 0.008
Leukocytes on admission (× 109/L) 2.9 ± 3.7 2.8 ± 3.5 3.3 ± 4.9 NS (0.569)
Platelets on admission (× 109/L) [median] 72.7 [60] 72.9 ± [60] 71.1 [59] NS (0.809)
Prothrombin time INR on admission 1.8 ± 0.7 1.8 ± 0.7 1.9 ± 0.7 NS (0.050)
Serum sodium on admission (mmol/L) 137.8 ± 5.7 137.9 ± 5.4 137.0 ± 8.0 NS (0.471)
AST on admission (U/L) [median] 88.8 [62] 87.5 [64] 98.3 [51] NS (0.498)
ALT on admission (U/L) [median] 67.2 [39] 67.4 [40] 65.8 [34] NS (0.938)
Total bilirubin on admission (μmol/L) [median] 145.4 [51] 130.0 [50] 244.5 [96] 0.003
A-a gradient on admission (mmHg) [median] 25.1 [17] 22.8 [17] 43.3 [18] 0.039
Serum creatinine on admission (μmol/L) [median] 97.2 [77] 92.2 [75] 114.9 [84] NS (0.064)
Hepatorenal syndrome, n (%) 29 (9) 22 (8) 7 (17) NS (0.079)
MAP on admission (mmHg) 86.1 ± 12.4 86.3 ± 12.7 84.7 ± 10.3 NS (0.427)
Child-Pugh points on admission 10.1 ± 2.6 9.9 ± 2.7 11.1 ± 2.0 0.010
MELD score on admission 17.6 ± 9.0 17.1 ± 8.9 21.4 ± 9.7 0.025
RIFLE on admission (No AKI/Risk/Injury/Failure) 286/16/9/12 250/13/9/9 36/3/0/3 NS (0.449)
SOFA score on admission 5.1 ± 2.7 4.8 ± 2.5 6.7 ± 3.3 0.001
Anesthesia time during operation (hours) 12.1 ± 1.8 12.1 ± 1.9 12.4 ± 1.5 NS (0.362)
Donor type (DDLT /LDLT) 91/232 74/207 17/25 0.018
Total operative time (mins) [median] 687.1 [683] 685.6 [683] 697.2 [682] NS (0.589)
Cold ischemia time (mins) [median] 85.0 [15] 74.8 [15] 166.4 [17] NS (0.125)
Warm ischemia time (mins) [median] 128.2 [122] 126.3 [121] 141.1 [129] NS (0.115)
Graft-to-recipient weight ratio (%) 1.0 ± 0.3 1.0 ± 0.3 1.1 ± 0.5 NS (0.125)
Blood loss volume during operation (ml) [median] 3034 [2000] 2672 [1840] 4430 [2000] 0.014
Length of ICU stay (days) [median] 21.0 [14] 19.2 [14] 33.6 [24] 0.002
Length of hospital stay (days) [median] 47.8 [38] 46.7 [38] 54.7 [44] NS (0.215)
Values in bold are statistically significant (P-value < 0.05)
There were significant differences in BMI on admission, history of chronic kidney disease, presence of proteinuria on admission, hemoglobin on admission, total
bilirubin on admission, A-a gradient on admission, Child-Pugh points on admission, MELD score on admission, SOFA score on admission, blood loss volume during
operation, and length of ICU stay
Abbreviation: M male, F female, ICU intensive care unit, MAP mean arterial pressure, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine
aminotransferase, DM diabetes mellitus, MELD model for end-stage liver disease, SOFA sequential organ failure assessment, AKI acute kidney injury, DDLT deceased
donor liver transplantation, LDLT living donor liver transplantation
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those with newly onset proteinuria tended to have
longer cold ischemia time. While in patients who
received living-donor grafts, those with newly onset
proteinuria tended to have longer warm ischemia
time.
The univariate analysis showed that 9 (Table 5) out
of the 31 variables (Table 2) were good prognostic
indicators for in-hospital mortality. On performing
the multivariate analysis, we recognized presence of
proteinuria and SOFA determined on the first day of
ICU admission as having independent prognostic sig-
nificance (Table 5). Regression coefficients of these
variables were used to calculate the odds of death in
each patient as follows:
Logarithm of odds of death = −2.471 + 1.320 × Protein-
uria + 0.157 × SOFA score.
Table 3 Primary liver diseases and presumptive causes of AKI after operation according to in-hospital mortality
All patients Survivors Non-survivors P-value
n = 323 n = 281 n = 42
Primary liver disease 323 (100) 281 (100) 42 (100)
Alcoholic, n (%) 16 (5) 12 (4) 4 (10) NS (0.254)
Hepatitis B, n (%) 111 (34) 100 (36) 11 (26) NS (0.848)
Hepatitis C, n (%) 31 (10) 23 (8) 8 (19) 0.003
Hepatoma, n (%) 3 (1) 3 (1) 0 (0) NS (1.000)
Alcoholic + hepatitis B, n (%) 21 (6) 15 (7) 2 (5) NS (1.000)
Alcoholic + hepatitis C, n (%) 5 (2) 5 (2) 0 (0) NS (1.000)
Alcoholic + hepatoma, n (%) 3 (1) 3 (1) 0 (0) NS (1.000)
Hepatitis B + hepatitis C, n (%) 17 (5) 14 (5) 3 (7) NS (0.723)
Hepatitis B + hepatoma, n (%) 49 (15) 43 (15) 6 (14) NS (0.172)
Hepatitis C + hepatoma, n (%) 31 (10) 29 (10) 2 (5) NS (0.134)
Alcoholic + hepatitis B + hepatoma, n (%) 2 (1) 1 (1) 1 (2) NS (0.429)
Other causes, n (%)a 34 (10) 29 (10) 5 (12) NS (0.787)
Presence of AKI after transplantation (Post-OP day1) 125 (39) 101 (36) 24 (57) 0.011
Prerenal type of AKI, n (%) 2 (1) 2 (1) 0 (0) NS (1.000)
Infection related AKI, n (%) 42 (13) 31 (11) 11 (26) 0.006
Nephrotoxic agent exposure related AKI, n (%) 6 (2) 6 (2) 0 (0) NS (0.601)
Mixed type and other causes of AKI, n (%)b 75 (23) 62 (22) 13 (31) NS (0.236)
Values in bold are statistically significant (P-value < 0.05)
Hepatitis C virus infection was independently associated with in-hospital mortality
Presence of infection related AKI on the first day after transplantation was independently associated with in-hospital mortality
aBiliary cirrhosis, biliary sclerosis, autoimmune hepatitis, Wilson’s disease, polycystic liver disease, drugs, and unknown causes
bMultifactor related, ischemia/reperfusion injury, or unknown cause
Table 4 Operation time according to newly onset proteinuria after transplantation
Patients with no proteinuria
on admission
Patients with newly onset
proteinuria on post-OP day 1
Patients with no newly onset
proteinuria on post-OP day 1
P-value
LDLT n = 208 n = 65 (31.2 %) n = 143 (68.8 %)
Total operative time (mins) [median] 703.9 [695] 789.3 [811] 707.6 [691] NS (0.087)
Cold ischemia time (mins) [median] 85.4 [14] 27.9 [15] 21.9 [13] NS (0.659)
Warm ischemia time (mins) [median] 128.2 [130] 194.0 [182] 127.6 [133] 0.004
DDLT n = 70 n = 47 (67.1 %) n = 23 (32.9 %)
Total operative time (mins) [median] 640.0 [633] 646.2 [653] 625.8 [632] NS (0.876)
Cold ischemia time (mins) [median] 651.3 [583] 756.5 [634] 552.0 [541] 0.039
Warm ischemia time (mins) [median] 113.5 [91] 114.0 [90] 101.4 [90] NS (0.737)
Values in bold are statistically significant (P-value < 0.05)
In the LDLT group, patients with newly onset proteinuria had significantly longer warm ischemia time
In the DDLT group, patients with newly onset proteinuria had significantly longer cold ischemia time
Abbreviation: DDLT deceased donor liver transplantation, LDLT living donor liver transplantation
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Calibration and discrimination of the scoring systems
Table 6 showed values of calibration and discrimination
of proteinuria, CP points, MELD, RIFLE, and SOFA in
predicting 90-day mortality. For assessing calibration,
the number of observed and predicted mortality was
compared by Hosmer-Lemeshow goodness-of-fit. Dis-
criminatory power was assessed by AUROC. On basis
of the ROC analysis, discriminatory ability of SOFA
and MELD determined on preoperative, postoperative
days 1, 7, and 14 were better than that of CP points and
proteinuria.
The proteinuria plus SOFA score [following
variables were applied for the calculation: presence of
proteinuria (1 point) and SOFA] was defined as the
addition of the two variables, with sum ranging from 0
to 25 [4]. The discriminatory ability of this score
seemed to be superior to that of other evaluating sys-
tems, including proteinuria, CP points, MELD, RIFLE,
SOFA, and proteinuria plus nonrenal SOFA scores.
AUROC curves were highest for proteinuria plus
SOFA on postoperative day 7 to predict 90-day mor-
tality (0.907 ± 0.041). AUROC value for proteinuria
plus SOFA determined on postoperative day 1 was sig-
nificantly higher than that for proteinuria, RIFLE, CP
points, and MELD. AUROC for proteinuria plus SOFA
determined on postoperative day 7 and 14 were sig-
nificantly higher than that for proteinuria, RIFLE, and
CP points.
Indices for predicting short-term prognosis
For evaluation and validation of the scoring systems, we
compared the sensitivity, specificity, and overall correct-
ness of prediction at cut-off values which could offer the
highest Youden index (Table 7). At preoperative, postop-
erative days 1, 7, and 14, The proteinuria plus SOFA had
the best Youden index and overall correctness in pre-
dicting 90-day mortality
In this study population, 45 patients had proteinuria
while 278 patients had no proteinuria on ICU admission.
Patients with proteinuria on admission had higher inci-
dence of AKI (26.8 % vs. 8.8 %, p < 0.001), severe infection
episodes requiring prolonged courses of antibiotics or ino-
tropic agents (48.8 % vs. 30.7 %, p = 0.023), hospital death
(31.1 % vs. 10.1 %, p < 0.001), and 90-day mortality (37.7 %
vs. 10.9 %, p < 0.001) than those without proteinuria.
Figure 1 illuminates the significantly different cu-
mulative survival rates between patients with and
without proteinuria as well as the similar cumulative
survival rates between patients with and without SCr
level elevation (Increase in SCr ≥ 1.5 × baseline) on
ICU admission (before transplantation). Fig. 2 shows
the weak correlation of proteinuria and SCr mea-
sured on ICU admission (P = 0.143). Fig. 3 illustrates
significant increases in the prevalence of proteinuria
during the time (starting before transplantation to
14 days postoperatively) among hospital and 90-day
mortality groups but not survival groups.
Table 5 Variables showing prognostic significance for in-hospital mortality
Parameters Beta Coefficient Standard error Odds ratios (95 % CI) P-value
Univariate logistic regression
BMI on admission (kg/m2) −0.247 0.050 0.781 (0.708–0.861) <0.001
History of chronic kidney disease 1.167 0.437 3.211 (1.364–7.557) 0.008
Proteinuria on admission 1.480 0.398 4.391 (2.011–9.587) <0.001
Hemoglobin on admission (g/dL) −0.218 0.083 0.804 (0.683–0.947) 0.009
Total bilirubin on admission (mg/dL) 0.037 0.011 1.038 (1.015–1.061) 0.001
Donor type (DDLT /LDLT) −0.41 0.169 0.664 (0.477–0.925) 0.015
A-a gradient on admission 0.009 0.003 1.009 (1.002–1.016) 0.007
Child-Pugh points on admission 0.176 0.070 1.193 (1.040–1.368) 0.012
MELD score on admission 0.046 0.056 1.047 (0.999–1.098) NS (0.056)
SOFA score on admission 0.219 0.057 1.245 (1.114–1.391) <0.001
Blood loss volume during operation (ml) <0.001 <0.001 1.000 (1.000–1.000) 0.003
Length of ICU stay (days) 0.018 0.006 1.018 (1.007–1.029) 0.002
Multivariate logistic regression
Proteinuria on admission 1.320 0.478 3.745 (1.468–9.554) 0.006
SOFA on admission 0.157 0.067 1.170 (1.027–1.333) 0.019
Constant −2.471 0.245 0.085 <0.001
On performing multivariate logistic regression, the presence of proteinuria on admission and SOFA score on admission had independent prognostic
significance for assessing in-hospital mortality
Abbreviation: MELD model for end-stage liver disease, SOFA sequential organ failure assessment
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Discussion
In the current research, overall hospital survival rate was
87.0 % (281/323), which is in agreement with what had
been presented in the literature [8, 18, 19]. Our investi-
gation found that both presence of proteinuria and
SOFA score determined on the first day of admission
to the ICU were significantly correlated to in-hospital
mortality (Tables 2 and 5). Analytical results also proved
that discriminatory ability of SOFA was better than those
of CP points, RIFLE, and MELD. One notable finding of
this study was that presence of proteinuria in combination
with SOFA has an even more superior discriminatory
Table 6 Calibration and discrimination for the scoring methods used in predicting 90-day mortality
Calibration Discrimination
Goodness-of-fit (x2) df p AUROC ± SE 95 % CI P
On admission
Proteinuria - - - 0.582 ± 0.053 0.479–0.685 NS (0.100)
Child-Pugh points 10.157 7 0.180 0.580 ± 0.041 0.499–0.662 NS (0.087)
MELD score 5.845 8 0.665 0.609 ± 0.067 0.418–0.680 NS (0.067)
RIFLE ─ ─ ─ 0.577 ± 0.067 0.355–0.618 NS (0.845)
SOFA 1.618 5 0.899 0.648 ± 0.049 0.552–0.745 0.002
Proteinuria plus SOFA 1.047 5 0.959 0.659 ± 0.052 0.557–0.761 0.002
Proteinuria plus nonrenal SOFA 6.347 6 0.385 0.658 ± 0.055 0.550–0.765 0.002
Postoperative day 1
Proteinuria - - - 0.609 ± 0.090 0.432–0.786 NS (0.240)
Child-Pugh points 2.438 5 0.786 0.639 ± 0.062 0.479–0.721 NS (0.142)
MELD score 5.947 8 0.653 0.705 ± 0.044 0.620–0.791 <0.001
RIFLE 2.684 2 0.261 0.626 ± 0.048 0.531–0.720 0.007
SOFA 3.063 8 0.930 0.761 ± 0.043 0.676–0.845 <0.001
Proteinuria plus SOFA 7.406 6 0.285 0.828 ± 0.062 0.707–0.949 <0.001
Proteinuria plus nonrenal SOFA 11.595 5 0.041 0.823 ± 0.078 0.670–0.977 0.001
Postoperative day 7
Proteinuria - - - 0.757 ± 0.056 0.647–0.866 <0.001
Child-Pugh points 6.365 4 0.173 0.750 ± 0.065 0.593–0.847 0.001
MELD score 26.161 8 0.001 0.856 ± 0.038 0.782–0.930 <0.001
RIFLE 9.602 2 0.008 0.825 ± 0.042 0.742–0.908 <0.001
SOFA 6.073 6 0.415 0.899 ± 0.031 0.838–0.961 <0.001
Proteinuria plus SOFA 8.625 6 0.196 0.907 ± 0.041 0.825–0.988 <0.001
Proteinuria plus nonrenal SOFA 7.856 6 0.249 0.903 ± 0.038 0.828–0.978 <0.001
Postoperative day 14
Proteinuria - - - 0.773 ± 0.067 0.642–0.904 0.005
Child-Pugh points 3.469 3 0.325 0.783 ± 0.052 0.682–0.885 <0.001
MELD score 134.84 8 <0.001 0.850 ± 0.056 0.740–0.960 <0.001
RIFLE 1.658 2 0.436 0.780 ± 0.050 0.681–0.879 <0.001
SOFA 24.495 7 0.001 0.892 ± 0.044 0.806–0.978 <0.001
Proteinuria plus SOFA 3.987 7 0.781 0.900 ± 0.042 0.819–0.982 <0.001
Proteinuria plus nonrenal SOFA 5.009 7 0.659 0.894 ± 0.038 0.819–0.969 <0.001
Values in bold are statistically significant (P-value < 0.05)
On ICU admission day (before transplantation): The prediction accuracy of the SOFA score was better than those of the Child-Pugh points, MELD score and RIFLE.
The proteinuria plus SOFA score has an even better discriminatory power than the SOFA score
On post-transplant day 1, 7, 14: The prediction accuracy of the SOFA and MELD score was better than that of the Child-Pugh points. The proteinuria plus SOFA
score has an even better discriminatory power than the SOFA score
Abbreviation: MELD, model for end-stage liver disease; SOFA, sequential organ failure assessment; df, degree of freedom; AUROC, areas under the receiver
operating characteristic curve; SE, standard error; CI, confidence intervals; NS, not significant
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power than SOFA alone (Table 6). Moreover, proteinuria
plus SOFA also had the highest Youden index and the best
overall correctness of prediction (Table 7).
AKI is a common complication in patients with decom-
pensated liver disease, and its occurrence is correlated to
poor prognosis [20]. Recently, several promising urinary
protein biomarkers have been proved to be remarkably
helpful for detecting AKI, such as Calprotectin, neutrophil
gelatinase-associated lipocalin (NGAL), cystatin C,
interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1),
and L-type or liver-type fatty acid-bind protein (LFABP)
[2, 21–24]. The presence of protein in urine might reflect
structural or functional defects of the glomerular ca-
pillary barrier or the reabsorption receptors in the
Table 7 Prediction of subsequent 90-day mortality
Predictive factors Cutoff point Youden index Sensitivity (%) Specificity (%) Overall correctness (%)
Proteinuria
On admission positive 0.16 28 88 58
Postoperative day 1 positive 0.22 64 58 61
Postoperative day 7 positive 0.51 85 66 76
Postoperative day 14 positive 0.55 90 65 77
Child-Pugh points
On admission 12 0.17 95 22 59
Postoperative day 1 10 0.26 90 37 64
Postoperative day 7 9 0.42 60 82 71
Postoperative day 14 8 0.42 50 92 71
MELD score
On admission 15 0.19 65 56 61
Postoperative day 1 22 0.27 60 71 66
Postoperative day 7 20 0.58 69 87 78
Postoperative day 14 23 0.62 75 87 81
RIFLE
On admission I category 0.04 7 97 52
Postoperative day 1 I category 0.20 57 64 61
Postoperative day 7 I category 0.56 72 82 77
Postoperative day 14 R category 0.60 74 82 78
SOFA
On admission 5 0.23 52 71 62
Postoperative day 1 11 0.41 77 64 71
Postoperative day 7 7 0.70 83 87 84
Postoperative day 14 7 0.69 85 84 84
Proteinuria plus SOFA
On admission 5 0.26 57 70 63
Postoperative day 1 12 0.54 79 75 77
Postoperative day 7 8 0.72 85 85 85
Postoperative day 14 8 0.72 89 83 86
Proteinuria plus nonrenal SOFA
On admission 5 0.26 54 76 63
Postoperative day 1 12 0.54 54 100 77
Postoperative day 7 8 0.68 86 82 84
Postoperative day 14 7 0.67 100 67 84
Optimal cutoff points for predicting 3-month mortality were derived from receiver operator characteristic analysis. On admission (pre-transplant), post-transplant day 1, 7, and
14, the Youden index and overall correctness for predicting 3-month mortality were higher for the proteinuria plus SOFA score than those for the proteinuria, Child-Pugh
points, MELD score, RIFLE criteria, SOFA, and proteinuria plus nonrenal SOFA scores
Abbreviation: MELD model for end-stage liver disease, SOFA sequential organ failure assessment
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renal proximal tubules. Proteinuria is not only a sen-
sitive indicator but also a risk factor for acute kidney
injury [25]. Increasing evidence has indicated that
proteinuria itself may activate intrarenal complement
cascade, upregulate proximal tubular inflammatory
and fibrogenic gene, trigger apoptotic response, and
further lead to spreading of renal tubulointerstitial
damage and adverse outcomes [26–31]. In the litera-
ture, urine albumin to creatinine ratio (UACR) is a
precise method for measurement of albuminuria and
identification of renal dysfunction [32, 33]. Neverthe-
less, previous study had documented that preoperative
proteinuria could accurately predict the development
of AKI in patients undergoing operation, irrespective
of it is determined by UACR or urine dipstick ana-
lysis [34]. Previous reports also demonstrated that
calculating urinary calprotectin/creatinine or NGAL/
creatinine ratio does not lead to higher prediction
accuracy than using urinary calprotectin or NGAL
alone [2, 24]. In this study, proteinuria was detected
with the dipstick analysis, the advantages of this
examination are inexpensive and easily performed and
interpreted. Analyzed data showed presence of proteinuria
on ICU admission (before transplantation) was correlated
to increased risks of AKI, severe infection episodes,
in-hospital mortality, and 90-day mortality (Fig. 1).
The occurrence of AKI after transplantation,
Fig. 1 Survival Functions Kaplan-Meier survival analysis in 323 patients according to the data measured before receiving liver transplantation. a
Cumulative survival rates differed significantly for patients with proteinuria (n = 45) and those without proteinuria (n = 278) on the first day of ICU
admission. b Cumulative survival rates did not differ significantly for patients with SCr level elevation (Increase in SCr≥ 1.5 × baseline) (n = 28)
and those without SCr elevation (n = 295) on the first day of ICU admission. *Abbreviation: SCr, serum creatinine
Fig. 2 Correlations of proteinuria and SCr measured on the first day of
ICU admission for in-hospital mortality. The proteinuria is not correlated
significantly (p = 0.143) with SCr. *Abbreviation: SCr, serum creatinine
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especially infection related AKI, was correlated to a
markedly lower chance of survival (Table 3). Measure-
ment of preoperative proteinuria might be useful to
preemptively identify patients who have increased risk
of AKI and severe infection episodes. Based on the
observed results, it seems that avoiding nephrotoxic
agents and choosing therapy carefully are crucial ways
of renoprotection for patients present with proteinuria
before transplant. More intensive postoperative care
and infection prevention strategies, such as more
aggressive prophylactic antimicrobial regimens and
strict practice for infection prophylaxis, might also
help to prevent further adverse outcomes for these
patients. Further well-powered research is needed to
study this issue.
Among patients undergoing liver transplant, deve-
lopment of renal dysfunction may be attributed to in-
traoperative caval cross-clamping with vascular outflow
obstruction, reperfusion injury, significant infectious
event, bleeding, perioperative hypotension with high
vasopressor requirement, large-volume transfusions,
exposure to nephrotoxic agents or use of calcineurin
inhibitors [35–37]. As part of the acute phase response,
general vascular permeability increases and the urinary
excretion of protein and albumin occur within several
hours after operation [38]. In our study, the decreased-
donor graft recipients who had prolonged cold ische-
mia time and the living-donor graft recipients who had
longer warm ischemia time, were found to have signifi-
cantly higher incidences of newly onset proteinuria on
the first day after operation. These findings are consist-
ent with previous studies [39–43]. Moreover, the preva-
lence of proteinuria decreased significantly within
7 days after operation in the in-hospital and 90-day
survival groups but not in the mortality groups (Fig. 3).
It implies that patients with poor physiologic adapta-
bility are much more intolerable to the transient
hemodynamic change of kidney. In addition, the per-
sistence of proteinuria in serial assessment after liver
transplantation might represent delayed recovery from
the major operation and signify poor short-term
prognosis.
Early detection of AKI after liver transplant could
potentially retard the progression of renal dysfunction
and prevent further adverse outcomes by prompt inter-
vention [36, 44]. Many researches have shown that
SOFA can completely present courses of major organ
dysfunction and dynamic changes of illness severity after
acute insults [45]. We have proposed that SOFA deter-
mined on postoperative day 7 has good predictive
performance in short-term outcome of patients receiving
liver transplant [8]. However, the renal parameter of the
SOFA score, SCr concentration, does not seem to
elevate until decline of renal function over than 50 %.
This means that early detecting AKI by SOFA is hardly
possible [36]. Our data revealed that absolute concentra-
tion and relative change of SCr levels are not signifi-
cantly correlated to the presences of proteinuria and
patient outcomes (Table 2, Figs. 1, 2), which highlights
that SCr concentration is inaccurate for discovering
kidney injury among patients with decompensated liver
disease [46]. On the contrary, the occurrence of protein-
uria might represent subtle renal function changes, and
it also signifies generalized inflammatory environment
and poor prognosis (correlation between proteinuria
and CRP, before operation: P < 0.001; postoperative
Fig. 3 The prevalence of proteinuria for the (a) in-hospital survival group (living, n = 281) and mortality group (dead, n = 42) and (b)
90-day survival group (living, n = 277) and mortality group (dead, n = 46) during the ICU admission day and postoperative days 1, 7,
and 14. The prevalence of proteinuria significantly increased during this period among the in-hospital and 90-day mortality groups
but not in the survivor groups (* P < 0.05)
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day 1: P = 0.005). In this study, the combination of
proteinuria improves the flaws of SCr and the prediction
ability of SOFA during perioperative time, particularly on
postoperative day 1 (an increase in the AUROC from
0.761 to 0.828) (Tables 6). These exciting findings seem to
demonstrate that presence of proteinuria could pro-
vide outstanding early prognostic prediction for pa-
tients undergoing liver transplantation.
Despite the promising results obtained in this research,
there are some possible limitation should be acknowledged.
Firstly, this research was performed in just one tertiary
medical center, so our results might not be exactly general-
ized to dissimilar patient population. Secondly, owing to
the retrospective nature of our study, not every clinical
factor was available. Thirdly, the patient population con-
tained a high proportion of hepatitis B viral infection (34 %)
and may present as a special subgroup in the cirrhotic
patients. Fourthly, predictive precision of logistic
regression models is not perfect and flawless. Finally,
the prognostic tools were applied on patients already
admitted to the ICU, and were not used as a pread-
mission screening test, this might skew the analyses.
Conclusions
To conclude, this study showed that preoperative pro-
teinuria is a significant risk factor of hospital mortality
in patients undergoing liver transplantation. For patients
exhibiting proteinuria before transplant, we suggest
watch out for infection episodes, carefully choose therapy
and do prompt intervention to prevent further adverse
outcomes. Avoiding prolonged cold or warm ischemia
time of transplantation could also reduce organ injury
from reperfusion. The presence of proteinuria in serial
assessment after liver transplantation has been proven to
have early prognostic predictive effect and to assist the
SOFA score with better discriminatory power in predict-
ing short-term outcome. For these reasons, we recom-
mend surveying the presence of proteinuria in
preoperative and postoperative serial assessment. Protein-
uria is supposed to be recognized as an important negative
predictor for short-term survival of liver transplant
patients.
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